Prediction of chemo-response in serous ovarian cancer

[1] Gilks CB(2009)Ovarian carcinoma pathology and genetics: recent advances Hum Pathol 40 1213-23

[2] Prat J(2013)Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently? J Clin Oncol 31 2362-6

[3] Friedlander ML(1997)Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines Cancer Res 57 850-6

[4] Stockler MR(1994)Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells Cancer Res 54 5911-13

[5] Butow P(2012)Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways J Oncol 2012 737981-92

[6] King MT(2008)Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel Br J Cancer 99 1103-26

[7] McAlpine J(2007)A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy Clin Cancer Res 13 6984-94

[8] Tinker A(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-16

[9] Ledermann JA(2010)A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types Oncol Rep 24 489-2009

[10] Johnson SW(2010)A population-based gene signature is predictive of breast cancer survival and chemoresponse Int J Oncol 36 607-6

[1] Gilks CB(2009)Ovarian carcinoma pathology and genetics: recent advances Hum Pathol 40 1213-23

[2] Prat J(2013)Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently? J Clin Oncol 31 2362-6

[3] Friedlander ML(1997)Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines Cancer Res 57 850-6

[4] Stockler MR(1994)Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells Cancer Res 54 5911-13

[5] Butow P(2012)Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways J Oncol 2012 737981-92

[6] King MT(2008)Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel Br J Cancer 99 1103-26

[7] McAlpine J(2007)A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy Clin Cancer Res 13 6984-94

[8] Tinker A(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-16

[9] Ledermann JA(2010)A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types Oncol Rep 24 489-2009

[10] Johnson SW(2010)A population-based gene signature is predictive of breast cancer survival and chemoresponse Int J Oncol 36 607-6